share_log

Pfizer | 8-K: Poll Results of Pfizer Meeting

Pfizer | 8-K: Poll Results of Pfizer Meeting

輝瑞 | 8-K：輝瑞會議決議公告
美股sec公告 ·  04/29 22:22
牛牛AI助理已提取核心訊息
On April 25, 2024, Pfizer Inc. held its Annual Meeting of Shareholders, where several key proposals were voted upon. The nominees for Pfizer's Board of Directors were elected to serve until the next annual meeting, with votes for each nominee ranging from 3,416,127,786 to 3,641,520,694, and varying amounts of votes against and abstentions. Additionally, the selection of KPMG LLP as the company's independent registered public accounting firm for the fiscal year 2024 was ratified with a significant majority of 4,315,675,552 votes for approval. Shareholders also approved the Amended and Restated Pfizer Inc. 2019 Stock Plan and, on an advisory basis, the compensation of the Company's Named Executive Officers. However, shareholder proposals to Adopt an Independent Board Chair Policy, Publish a Congruency Report on Political, Lobbying, Electioneering Expenditures, and Publish a Report on Corporate Contributions were not approved. One proposal to Amend the Director Resignation Process was withdrawn and not presented at the meeting. The report was officially signed by Margaret M. Madden, Senior Vice President and Corporate Secretary, on April 29, 2024.
On April 25, 2024, Pfizer Inc. held its Annual Meeting of Shareholders, where several key proposals were voted upon. The nominees for Pfizer's Board of Directors were elected to serve until the next annual meeting, with votes for each nominee ranging from 3,416,127,786 to 3,641,520,694, and varying amounts of votes against and abstentions. Additionally, the selection of KPMG LLP as the company's independent registered public accounting firm for the fiscal year 2024 was ratified with a significant majority of 4,315,675,552 votes for approval. Shareholders also approved the Amended and Restated Pfizer Inc. 2019 Stock Plan and, on an advisory basis, the compensation of the Company's Named Executive Officers. However, shareholder proposals to Adopt an Independent Board Chair Policy, Publish a Congruency Report on Political, Lobbying, Electioneering Expenditures, and Publish a Report on Corporate Contributions were not approved. One proposal to Amend the Director Resignation Process was withdrawn and not presented at the meeting. The report was officially signed by Margaret M. Madden, Senior Vice President and Corporate Secretary, on April 29, 2024.
2024年4月25日，輝瑞公司舉行了年度股東大會，對幾項關鍵提案進行了表決。輝瑞董事會提名人當選的任期至下屆年會，每位被提名人的選票從3,416,127,786票到3,641,520,694票不等，反對票和棄權票數目各不相同。此外，畢馬威會計師事務所被選爲公司2024財年獨立註冊會計師事務所的決定以4,315,675,552票的絕大多數獲得批准。股東們還批准了經修訂和重述的輝瑞公司2019年股票計劃，並在諮詢基礎上批准了公司指定執行官的薪酬。但是，股東關於通過獨立董事會主席政策、發佈政治、遊說、競選支出一致性報告以及發佈企業捐款報告的提案未獲批准。一項修改董事辭職程序的提案被撤回，沒有在會議上提出。該報告由高級副總裁兼公司秘書瑪格麗特·馬登於2024年4月29日正式簽署。
2024年4月25日，輝瑞公司舉行了年度股東大會，對幾項關鍵提案進行了表決。輝瑞董事會提名人當選的任期至下屆年會，每位被提名人的選票從3,416,127,786票到3,641,520,694票不等，反對票和棄權票數目各不相同。此外，畢馬威會計師事務所被選爲公司2024財年獨立註冊會計師事務所的決定以4,315,675,552票的絕大多數獲得批准。股東們還批准了經修訂和重述的輝瑞公司2019年股票計劃，並在諮詢基礎上批准了公司指定執行官的薪酬。但是，股東關於通過獨立董事會主席政策、發佈政治、遊說、競選支出一致性報告以及發佈企業捐款報告的提案未獲批准。一項修改董事辭職程序的提案被撤回，沒有在會議上提出。該報告由高級副總裁兼公司秘書瑪格麗特·馬登於2024年4月29日正式簽署。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。